DFDA

Medroxyprogesterone Acetate (MPA) / Megestrol Acetate (Hormonal Therapy)

Treatment for Uterine Cancer

Typical Dosage: MPA 400-600mg daily, Megestrol Acetate 160mg 2-4 times daily

Effectiveness
35%
Safety Score
60%
Clinical Trials
40
Participants
5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
MPA 400-600mg daily, Megestrol Acetate 160mg 2-4 times daily
Time to Effect
1-3 months
Treatment Duration
6-12 months or longer for recurrent disease
Evidence Quality
MODERATE
Confidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$300
Monitoring:$2,000
Side Effect Mgmt:$200
Total Annual:$2,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$12,500/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$6,250
Cost per Remission
$10,000
Medroxyprogesterone Acetate (MPA) / Megestrol Acetate (Hormonal Therapy) Outcomes

for Uterine Cancer

Efficacy Outcomes
Overall Effectiveness
+35%
Response Rate
+40%
Remission Rate
+25%
Common Side Effects
Weight gain
+40%
Fluid retention
+30%
Hot flashes
+25%
Mood changes
+15%
Increased risk of venous thromboembolism
+7%

Sources:

nih.gov
nih.gov
researchgate.net

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
2 active trials recruiting for Medroxyprogesterone Acetate (MPA) / Megestrol Acetate (Hormonal Therapy) in Uterine Cancer

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer

NCT07831902RECRUITINGPHASE3
View Study
600 participants
INTERVENTIONAL
Bath, United Kingdom +11 more
Started: Jun 29, 2026

SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer

NCT07462663NOT YET RECRUITINGPHASE4
View Study
80 participants
INTERVENTIONAL
Started: Jan 1, 2027